AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02278510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium DTPA
Description: Gadolinium DTPA is a contrast agent which will be added to topotecan to allow the investigators to observe where topotecan goes in tumors. Gadolinium DTPA is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
Study NCT02278510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleveland Multiport Catheter
Description: The Cleveland Multiport Catheter is a device that is not approved by the FDA and so it is classified as an investigational device. It has been designed to deliver drugs and other agents intended to treat cancers directly into the affected tissues. The Cleveland Multiport Catheter can be placed into a brain tumor only in the operating room. It is placed during an operation to perform a biopsy of brain tumors. Following the biopsy, a surgeon will place two catheters into the tumor with use of an image guided navigation system. Once each catheter has been placed, it will be secured into the scalp and the incision will be closed. The Cleveland Multiport Catheter will be left in place until the completion of the topotecan treatment.
Study NCT03439306 — intervention group
Intervention type: DEVICE
Intervention: Pulse Oximeter
Description: The Pulse Oximeter are placed on the left and right Index fingers of each subject of the healthy adult volunteer group to evaluate the SpO2 accuracy performance.
Study NCT02064803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastro-entero anastomosis only
Description: Gastro-entero anastomosis only
Study NCT02064803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric partitioning Plus Gastro-entero anastomosis
Description: Gastric partitioning Plus Gastro-entero anastomosis
Study NCT04195646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoVigilant CAD Software
Description: The CAD software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the CAD software is installed on a computer system unit that utilizes an an operating system.
Study NCT01729741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drain was inserted after thyroid surgery
Description: insertion of drain after thyroid surgery
Study NCT00005942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal daunorubicin citrate
Description: Given IV
Study NCT00005942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Description: Given IV
Study NCT00005942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04558060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Standardized Patient
Description: Computer program that presented a virtual human patient
Study NCT04558060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Academic Study
Description: Study of a summary of motivational interviewing concepts and techniques.
Study NCT02587676 — intervention group
Intervention type: OTHER
Intervention: Evatouch Super
Description: The deterioration of RDLs may differ between in vitro conditions and the conditions encountered in denture wearers. We conducted an in vivo study to investigate how resilient denture liners (RDLs) changed in hardness when embedded in complete maxillary dentures worn by patients for one month in a clinical setting. We hypothesized that the hardness one month after application of the RDLs would be affected by the age, the condition of the saliva, the occlusal force, type of denture used, the patients habits related to smoking, drinking, wearing dentures while sleeping, and using a denture cleanser.
Study NCT02006472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pridopidine
Description: 22.5 mg and 45 mg capsules
Study NCT02006472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules matching drug
Study NCT02006472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules matching drug
Study NCT01553656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib capsules
Description: cabozantinib capsules administered as 25-mg and 100-mg strengths once-daily until disease progression
Study NCT01553656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib tablets
Description: cabozantinib tablets administered as 20-mg and 60-mg strengths once-daily until disease progression
Study NCT00576355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy for Adolescents (IPSRT-A)
Description: IPSRT-A involves 20 weeks of individual therapy, incorporating informed psychological, behavioral, and practical strategies adapted to the developmental needs of adolescents.
Study NCT00576355 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: TAU includes the offering of educational information about bipolar disorder and referral to a mental health provider.
Study NCT04690686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LW-02 device immunopheresis combined with atezolizumab
Description: The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with standard dose immunotherapy (atezolizumab) to potentially enhancing its cytotoxic effect.
Study NCT04690686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LW-02 device immunopheresis combined with weekly paclitaxel
Description: The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with low dose chemotherapy to potentially enhancing its cytotoxic effect.
Study NCT04690686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LW-02 device immunopheresis
Description: The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
Study NCT03558659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positional therapy belt
Description: The positional therapy belt produced by SlumberBUMP will be used by stroke patients during sleep, which helps to avoid sleep in the supine position.
Study NCT01239953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty using the paclitaxel-eluting balloon
Description: Balloon angioplasty
Study NCT01239953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty using the everolimus-eluting stent
Description: Stent implantation
Study NCT03848325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Eight hour opportunity for sleep followed by 24 hours of sleep deprivation.
Study NCT01460212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI antidepressants
Description: SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
Study NCT01460212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy
Description: The essence of CBT is a learning process through which an appropriate pattern in cognitive and behavioral could be learn and stored as memory
Study NCT03909152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onapristone ER
Description: 50 mg PO BID (with dosage adjustments) until POD, unacceptable toxicity or withdrawal of consent.
Study NCT03909152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onapristone ER + Anastrozole
Description: Onapristone ER Patients will take 50 PO BID in the form of two 20 mg tablets and one 10 mg tablet taken with food and water twice daily. Patients will be prescribed anastrozole 1mg PO QD. Anastrozole will be taken once daily in the AM with patients morning dose of onapristone ER.
Study NCT04571944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant administered at a dose of 15 mg QD via oral tablet
Study NCT04571944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suvorexant-matching placebo administered QD via oral tablet
Study NCT04040569 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiomics on MRI
Description: Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic Shell feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence.
Study NCT02967991 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided liver biopsy
Description: Endoscopic ultrasound guided liver biopsy
Study NCT02967991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided liver biopsy
Description: Endoscopic ultrasound guided liver biopsy
Study NCT03197298 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel
Study NCT03197298 — intervention group
Intervention type: DRUG
Intervention: Ticagrelor
Study NCT01254136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB007839 300mg BID
Description: INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
Study NCT01254136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
Study NCT01254136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
Study NCT03486912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days.
Study NCT04298021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: * In AZD6738+Durvalumab cohort~  - AZD6738 240 mg bid on D15-D28 Every 4 weeks~* In AZD6738+ Olaparib cohort - AZD6738 160 mg qd on D1-7 Every 4 weeks
Study NCT04298021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg iv on D1 Every 4 weeks
Study NCT04298021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg bid on D1-28 Every 4 weeks
Study NCT02164123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal mobilization
Description: Experimental group
Study NCT02164123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Mobilization II
Description: Active comparator group
Study NCT02164123 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group
Study NCT02621320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D3 (Vi-De 3®. WILD) 6000IU daily over a period of 12 weeks.
Study NCT02621320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: alcohol-based solution 1.3ml daily over a period of 12 weeks.
Study NCT02104050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: 6 mL of Placebo Gel administered TID for 6 weeks
Study NCT02104050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLT1177 Gel
Description: 6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
Study NCT02117947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling
Description: Behavioral counseling used components of evidence-based smoking intervention treatment to promote maternal smokers efforts in reducing their children's exposure to secondhand smoke.
Study NCT02117947 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help control
Description: This intervention group received a comprehensive self-help manual that included information and advice about how to protect children from secondhand smoke (e.g., adopting a smokefree home and car.)
Study NCT01436851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Storage mite allergen extracts
Description: Nasal provocation with increasing doses of storage mite allergen extracts
Study NCT00440999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine artesunate
Study NCT00440999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Study NCT03447808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT03447808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT03447808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03486912 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days.
Study NCT03875378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Description: Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch
Study NCT03875378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo weekly patch
Study NCT04081493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-load blood flow restricted exercise
Description: Leg press and knee extension exercise 3 times per week for 8 weeks. Repetition scheme: 30-15-15-until exhaustion interspaced by 30 sec rest. 5 min free-flow rest between exercises
Study NCT03932344 — intervention group
Intervention type: DRUG
Intervention: Anakinra
Description: Anakinra according to prescription
Study NCT01856270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Participants with headache will be enrolled within the first 12 weeks after injury and will be randomly assigned to 2 groups (see Table 1 for summary of protocol). Group 1 will be assessed within 3 months of injury (baseline, Day 0) (when they will receive their initial ramp-up dosage containers; see Table 2 for dosing), Day 30 and Day 60 (to monitor compliance and distribute study drug), and for final outcome on Day 90. Group 2 will be assessed within 3 months of injury (baseline, Day 0) but will not receive medication until their Day 30 visit. Those in group 2 who report headache at Day 30 will receive their initial dosage container and will then be reassessed at Day 60 (to monitor compliance and distribute study drug) and Day 90 (final outcome).
Study NCT02933008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aNMT Biofeedback
Description: aNMT utilizes well-established visual feedback strategies to promote efficient, rapid and robust learning of complex movements. Athletes can discover how to move to create the desired feedback, even without explicit, conscious knowledge of how their movements relate to the visual pattern. aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine real-time transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention.
Study NCT02933008 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Biofeedback
Description: Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases.
Study NCT02933008 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neuromuscular Training
Description: Participants will complete a 12-session, pre-season training program, over 6 weeks.
Study NCT02933008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: Participants will complete a 12-session, pre-season training program, over 6 weeks.
Study NCT06047210 — intervention group
Intervention type: OTHER
Intervention: Blood Draws Data Collection
Study NCT03063892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Description: Tranexamic acid is an antifibrinolytic used to control bleeding
Study NCT03063892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution is used as the placebo comparator
Study NCT03675126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-5051
Description: SRP-5051 administered as an IV infusion.
Study NCT03772249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-HBVS
Description: DCR-HBVS is a synthetic ribonucleic acid interference (RNAi) drug that consists of a double-stranded oligonucleotide conjugated to N-acetyl-D-galactosamine (GalNAc) ligands. DCR-HBVS is a sterile solution of the siRNA (DCR-S219) at a concentration of 195 mg/mL in water for injection (WFI).
Study NCT03772249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DCR-HBVS
Description: Sterile 9% saline for injection.
Study NCT03302325 — intervention group
Intervention type: PROCEDURE
Intervention: research blood draws
Description: Twenty-five mL of peripheral blood (PB) will be collected for research. Blood will be collected in EDTA tubes and used to isolate ctDNA. For each subject we will request that he/she contribute 25 mL of plasma no more frequently than every 6 weeks, and at same time of standard of care blood draws and routine clinic visit, and for no more than 3 times (including baseline and end of study).
Study NCT03134196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Masked Placebo
Description: Oral Placebo
Study NCT03134196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Masked Oral Valacyclovir
Description: Oral Valacyclovir 1000 mg/day
Study NCT03521570 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Undergo intensity-modulated radiation therapy
Study NCT03521570 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03593525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPARK
Description: see above
Study NCT01210313 — intervention group
Intervention type: OTHER
Intervention: Physical exercise
Description: Defined exercise program
Study NCT03496844 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: F-18 fluciclovine-PET/CT scan
Description: PET/CT imaging with F-18 fluciclovine
Study NCT03193840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior wall osteotomy
Description: posterior wall osteotomy is conducted through Kocher-Langenbeck approach.
Study NCT01901445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational action with focal group
Study NCT03447808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01039792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl B12
Description: 75 µg/Kg subcutaneously injected once every 3 days